HER-2 Positive Breast Cancer
Conditions
Keywords
HER2, Breast cancer, Lipodox, Cyclophosphamide, Trastuzumab, Pertuzumab
Brief summary
Although neoadjuvant dual anti-HER2-targeted therapy, pertuzumab and trastuzumab, combined with taxanes increased the pCR rate for patients with early-stage HER2-positive breast cancer when compared with single blockade combined with chemotherapy, certain patients did not achieve pCR after receiving dual blockade or single blockade targeting HER2 combined with taxanes. Based on the cardiac safety and promising ORR rate of the regimens consisting of PLD and cyclophosphamide and trastuzumab in treating patients with HER2-positive breast cancer in the neoadjuvant or metastatic setting, the investigators hypothesized that dual blockades targeting HER2, trastuzumab and pertuzumab, combined with PLD and cyclophosphamide, will not only increase the pCR rate but also cause less cardiotoxicity for participants with residual cancer via core biopsy or non-clinical CR after receiving taxanes plus trastuzumab and pertuzumab or taxanes plus trastuzumab. The investigators also showed that ctDNA served as the surrogate prognostic marker for participants with HER2-positive EBC who received neoadjuvant trastuzumab-based regimens. In this study, the investigators will explore whether the combination of PLD (Lipo-Dox®, Liposomal Doxorubicin Injection), cyclophosphamide, trastuzumab, and pertuzumab can increase the pCR rate of participants with HER2-positive EBC if they have residual cancers (core biopsy, non-clinical CR, or positive ctDNA) after receiving a trastuzumab and taxanes-based NAT regimen. In addition, the cardiac safety, adverse effects, and clearance of ctDNA will be explored for these patients. The investigators further assess the feasibility of VAB (before operation) in these participants who achieved negative ctDNA after receiving Lipo-Dox® plus cyclophosphamide, trastuzumab, and pertuzumab.
Interventions
DRUGLipo-Dox®
Lipo-Dox®: 37.5 mg/m² on D1; every 21 days is one cycle, for a total of 4 cycles.
DRUGCyclophosphamide
Cyclophosphamide 600 mg/m² on D1, ; every 21 days is one cycle, for a total of 4 cycles.
Trastuzumab 6 mg/kg on D2; every 21 days is one cycle, for a total of 4 cycles.
DRUGPertuzumab
Pertuzumab 420 mg on D2; every 21 days is one cycle, for a total of 4 cycles.
Sponsors
National Taiwan University Hospital
TTY Biopharm
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Diagnosis: HER2-positive Primary Invasive Breast Cancer Patients must meet the following criteria for study entry: 1. Histologically confirmed invasive breast carcinoma 2. HER2-positive breast carcinoma 1. HER2-positive status will be based on pretreatment biopsy material and defined as an immunohistochemistry (IHC) score of 3+ and/or positive by fluorescence in situ hybridization (FISH) prospectively confirmed by a pathology laboratory before study enrollment. 2. FISH positivity is defined as a ratio of ≥ 2.0 for the number of HER2 gene copies to the number of signals for chromosome 17 copies. 3. Clinical stage at presentation: T1-4, N0-3, M0 (T1N0M0 tumors will not be eligible) 4. Patients must be willing to receive preoperative systemic chemotherapy with taxanes and HER-2-targeting treatment for at least 4 to 6 cycles. 1. Systemic therapy must consist of at least 4 to 6 cycles of chemotherapy with taxanes plus trastuzumab (TH) or 2. Systemic therapy must consist of at least 4 to 6 cycles of chemotherapy with taxanes plus trastuzumab and pertuzumab (THP). 3. After completion of 4 to 6 cycles of TH or THP, if the following clinical features and pathological characteristics are eligible for Lipo-Dox® and cyclophosphamide plus trastuzumab and pertuzumab: c.1 Core biopsy showed the residual invasive breast cancer. c.2 Breast echo or other imaging studies disclosed no complete remission. c.3 Complete remission of core biopsy or breast echo or other imaging studies, but positive for ctDNA. 5. Age ≥ 20 years. 6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. 7. Adequate organ function during screening, included: 1. Absolute neutrophil count ≥ 1,200 cells/mm3 2. Platelet count ≥ 100,000 cells/ mm3 3. Hemoglobin ≥ 9.0 g/dL; 4. Serum creatinine \< 1.5 × upper limit of normal (ULN) 5. International normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 ×ULN 6. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 1.5 ×ULN 7. Serum total bilirubin (TBILI) ≤ 1.0 ×ULN (within normal limits) 8. Serum alkaline phosphatase (ALK) ≤ 1.5 ×ULN 8. Screening LVEF ≥ 50% on echocardiogram (ECHO) or multiple-gated acquisition (MUGA) before receiving neoadjuvant chemotherapy with 4 to 6 courses of TH or THP and no decrease in LVEF by more than 10% absolute points from the pre-chemotherapy LVEF after 4 to 6 courses of TH or THP. 9. For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to remain abstinent or use single or combined contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and for at least 7 months after the last dose of study drug. 10. Documentation of hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies is required: this includes HB surface antigen (HBsAg) and/or total HB core antibody (anti-HBc) in addition to HCV antibody testing. If positive for HBsAg or positive for Anti-HBc, DNA testing for HBV will be performed. If active HBV infection is ruled out, the patient may be eligible. The most recent serologic testing must have occurred within 3 months prior to initiation of neoadjuvant therapy. If such testing has not been done, it must be performed during screening. 11. They should receive examination of HBV DNA to document no active HBV activation (if HBeAg-positive, or HBeAg-negative but abnormal liver function accompanied by ALT ≥ 2 normal limits during the half a year and HBV DNA \> 2000 IU/ml: indication of HBV activation). If test of HBsAg is positive and inactive, and they should receive prophylactic anti-HBV drugs during the enrollment period of this clinical trial.
Exclusion criteria
1. Stage IV (metastatic) breast cancer. 2. History of any prior (ipsilateral- or contralateral) breast cancer except lobular carcinoma in situ. 3. History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ (CIS) of the cervix, non-melanoma skin carcinoma, stage I uterine cancer, or other non-breast malignancies with an outcome similar to those mentioned above. 4. Patients for whom radiotherapy would be recommended for breast cancer treatment, but for whom it is contraindicated because of medical reasons (e.g., connective tissue disorder or prior ipsilateral breast radiation). 5. Current NCI common terminology criteria for adverse events (CTCAE) (Version 4.0): Grade ≥ 2 peripheral neuropathy. 6. Cardiopulmonary dysfunction as defined by any of the following: History of NCI CTCAE (Version 4.0): Grade ≥ 3 symptomatic congestive heart failure (CHF) or New York Heart Association (NYHA) criteria Class ≥ II. 7. Prior treatment with anthracycline or Lipo-Dox® 8. Current severe, uncontrolled systemic disease (e.g., clinically significant cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers). 9. For female patients, current pregnancy and/or lactation. 10. Any known active liver disease, for example, due to HBV, HCV, autoimmune hepatic disorders, or sclerosing cholangitis. * Patients who have positive HBV or HCV serologies without known active disease must meet the eligibility criteria for liver function on at least two consecutive occasions, separated by at least 1 week, within the 30 days-screening period.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pathological complete remission rate (pCR) | From enrollment to the end of operation. | Assessment of pathological specimens to determine when no cancer cells are detected in tissue samples (breast and lymph nodes) removed during surgery following preoperative treatment, such as chemotherapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with Lipodox-containing regimen-related adverse events of cardiac function as assessed by CTCAE v4.0 | From enrollment, before and after completion of Lipodox plus cyclophosphamide, trastuzumab, and pertuzumab, and 12 months after operation. | Cardiac echo to assess the left ventricle ejection fractions before and after completion of Lipo-Dox®-containing regimen |
| Clearance rate of circulating tumor DNA [ctDNA] | From enrollment, completion of TH or THP regimens, completion of Lipodox plus cyclophosphamide, trastuzumab, and pertuzumab, and at the end of operation. | Circulating tumor DNA (ctDNA) clearance refers to the transition from a detectable level of tumor-specific mutations in the bloodstream to undetectable levels following neoadjuvant treatment, including TH or THP regimen, or Lipodox plus cyclophosphamide, trastuzumab, and pertuzumab. |
| Number of participants with treatment with Lipo-Dox®-containing regimen-related adverse events as assessed by CTCAE v4.0. | From starting a Lipo-Dox®-containing regimen to the end of treatment at 4 weeks. | Adverse events of Lipodox plus cyclophosphamide, trastuzumab, and pertuzumab. |
| Percentage of patients with complete removal of lesion via vacuum-assisted biopsy | After completion of neoadjuvant chemotherapy regimens. | Comparison of the percentage of patients with a lack of pathology at the surgery between vacuum-assisted biopsy and surgical operation (ctDNAs are negative after completion of neoadjuvant chemotherapy). |
Countries
Taiwan
Contacts
CONTACTSung-Hsin Kuo, M.D.,Ph.D.
CONTACTChiun-Sheng Huang, M.D.,Ph.D.
Outcome results
None listed